Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coat Assembly and GTPases01:33

Coat Assembly and GTPases

Vesicles incorporate different coat protein subunits in different cell locations, which changes the properties of the coat, such as the shape and geometry of the transport vesicles. Thus, vesicle coat proteins also play a significant role in cargo selection.
Coat assembly depends on the local availability of phosphatidylinositol phosphates or PIPs and GTP-binding proteins. Adaptor proteins, which link the coat proteins to the membrane, bind to these PIPs and play a crucial role in controlling...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of Drug-like Inhibitors of the Human Caf1/CNOT7 poly(A)-Selective Nuclease Using Compound Screening.

Biomolecules·2025
Same author

Discovery of Substituted 5-(2-Hydroxybenzoyl)-2-Pyridone Analogues as Inhibitors of the Human Caf1/CNOT7 Ribonuclease.

Molecules (Basel, Switzerland)·2024
Same author

Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol.

International journal of pharmaceutics·2022
Same author

Distribution of a highly lipophilic drug cannabidiol into different lymph nodes following oral administration in lipidic vehicle.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2022
Same author

Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle.

Pharmaceutics·2021
Same author

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents.

Molecules (Basel, Switzerland)·2021
Same journal

Circular RNA circ_0001829 attenuates G2/M arrest to promote hepatocyte proliferation by sponging miR-3095-3p following liver injury.

Cell cycle (Georgetown, Tex.)·2026
Same journal

Identification of PGF+ endothelial cells associated with plaque instability in carotid atherosclerosis by scRNA-seq and RNA-seq analysis.

Cell cycle (Georgetown, Tex.)·2026
Same journal

BMSCs-derived exosomal miR-196a-5p promotes macrophage M2 polarization and osteogenesis in postmenopausal osteoporosis through regulating Rspo2/Wnt/β-catenin signaling.

Cell cycle (Georgetown, Tex.)·2026
Same journal

MicroRNA-6833-3p drives prostate cancer progression and stemness by targeting the NUMB-mediated NOTCH signaling pathway.

Cell cycle (Georgetown, Tex.)·2026
Same journal

OTUD5 promotes AML progression by stabilizing SLC7A11 to suppress ferroptosis.

Cell cycle (Georgetown, Tex.)·2026
Same journal

MITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming.

Cell cycle (Georgetown, Tex.)·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Cap in hand: targeting eIF4E.

Peter M Fischer1

  • 1Centre for Biomolecular Sciences and School of Pharmacy, University of Nottingham, Nottingham, UK. peter.fischer@nottingham.ac.uk

Cell Cycle (Georgetown, Tex.)
|July 15, 2009
PubMed
Summary
This summary is machine-generated.

Targeting the mRNA cap-binding protein eukaryotic initiation factor 4E (eIF4E) offers a promising anticancer strategy. Inhibiting eIF4E selectively targets cancer cells by disrupting essential protein synthesis.

More Related Videos

Analysis of Cap-binding Proteins in Human Cells Exposed to Physiological Oxygen Conditions
10:40

Analysis of Cap-binding Proteins in Human Cells Exposed to Physiological Oxygen Conditions

Published on: December 28, 2016

Identification of Protein Interacting Partners Using Tandem Affinity Purification
10:02

Identification of Protein Interacting Partners Using Tandem Affinity Purification

Published on: February 25, 2012

Related Experiment Videos

Last Updated: Jun 21, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Analysis of Cap-binding Proteins in Human Cells Exposed to Physiological Oxygen Conditions
10:40

Analysis of Cap-binding Proteins in Human Cells Exposed to Physiological Oxygen Conditions

Published on: December 28, 2016

Identification of Protein Interacting Partners Using Tandem Affinity Purification
10:02

Identification of Protein Interacting Partners Using Tandem Affinity Purification

Published on: February 25, 2012

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Biochemistry

Background:

  • The mRNA cap structure recognition by eukaryotic initiation factor 4E (eIF4E) is crucial for protein synthesis.
  • eIF4E activity is particularly vital for producing proteins associated with cancer hallmarks.
  • Transformed cells exhibit increased dependency on prosurvival factors, making translation targeting an attractive anticancer approach.

Purpose of the Study:

  • To explore the potential of targeting eIF4E as an anticancer strategy.
  • To validate the selective sensitivity of tumor cells to eIF4E inhibition.
  • To leverage emerging knowledge of eIF4E's functions, regulation, and structural biology for drug development.

Main Methods:

  • Proof-of-concept studies involving suppression of oncogenic eIF4E function.
  • Analysis of tumor cell sensitivity to protein synthesis inhibition at the eIF4E level.
  • Integration of current understanding of eIF4E's structural biology and regulation.

Main Results:

  • Suppression of eIF4E function selectively impacts tumor cells.
  • Tumor cells demonstrate sensitivity to the inhibition of protein synthesis mediated by eIF4E.
  • Emerging data on eIF4E functions, regulation, and structural biology support its pharmacological targeting.

Conclusions:

  • Targeting eIF4E is a viable and selective anticancer strategy.
  • The understanding of eIF4E's biology enables the development of novel therapeutics.
  • Pharmacological targeting of eIF4E holds promise for cancer treatment.